MYRIAD GENETICS INC (MYGN) Forecast, Price Target & Analyst Ratings

NASDAQ:MYGN • US62855J1043

Current stock price

4.36 USD
+0.08 (+1.87%)
At close:
4.25 USD
-0.11 (-2.52%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MYRIAD GENETICS INC (MYGN).

Forecast Snapshot

Consensus Price Target

Price Target
$7.54
+ 72.91% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 4, 2026
Period
Q1 / 2026
EPS Estimate
-$0.07
Revenue Estimate
206.43M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
53.33%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$7.54
Upside
+ 72.91%
From current price of $4.36 to mean target of $7.54, Based on 18 analyst forecasts
Low
$3.54
Median
$7.14
High
$18.90

Price Target Revisions

1 Month
-4.01%
3 Months
-8.34%

Price Target Summary

18 Wall Street analysts provided a forecast for the next 12 months for MYGN. The average price target is 7.54 USD. This implies a price increase of 72.91% is expected in the next year compared to the current price of 4.36.
The average price target has been revised downward by 8.34% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

MYGN Current Analyst RatingMYGN Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

MYGN Historical Analyst RatingsMYGN Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
53.33%
MYGN was analyzed by 18 analysts. The buy percentage consensus is at 53. So analysts seem to be rather neutral about MYGN.
In the previous month the buy percentage consensus was at a similar level.
MYGN was analyzed by 18 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-02-24UBSMaintains Neutral -> Neutral
2026-02-24Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-11-11Piper SandlerMaintains Overweight -> Overweight
2025-11-05Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-11-04TD CowenMaintains Hold -> Hold
2025-11-04UBSMaintains Neutral -> Neutral
2025-05-21ScotiaBankDowngrade Sector Outperform -> Sector Perform
2025-05-15Piper SandlerMaintains Overweight -> Overweight
2025-05-08Wells FargoDowngrade Overweight -> Equal-Weight
2025-05-07UBSMaintains Neutral -> Neutral
2025-05-07Raymond JamesReiterate Outperform -> Outperform
2025-05-07Goldman SachsMaintains Buy -> Buy
2025-04-17Goldman SachsMaintains Buy -> Buy
2025-04-09GuggenheimDowngrade Buy -> Neutral
2025-04-01ScotiaBankMaintains Sector Outperform -> Sector Outperform
2025-03-12Piper SandlerUpgrade Neutral -> Overweight
2025-03-04Piper SandlerMaintains Neutral -> Neutral
2025-03-03B of A SecuritiesMaintains Underperform -> Underperform
2025-02-25UBSMaintains Neutral -> Neutral
2025-02-25Raymond JamesReiterate Outperform -> Outperform
2025-02-12Craig-HallumInitiate Buy
2025-01-30Piper SandlerMaintains Neutral -> Neutral
2025-01-28Goldman SachsMaintains Buy -> Buy
2025-01-16Stephens & Co.Reiterate Equal-Weight -> Equal-Weight
2024-12-13B of A SecuritiesMaintains Underperform -> Underperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 4, 2026
Period
Q1 / 2026
EPS Estimate
-$0.07
Revenue Estimate
206.43M
Revenue Q2Q
5.38%
EPS Q2Q
-133.04%
Number of Analysts
15

Next Earnings Revisions

Revenue (1 Month)
-4.30%
Revenue (3 Months)
-3.56%
EPS (1 Month)
-7,631.87%
EPS (3 Months)
-977.67%

Next Earnings Summary

MYGN is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.07 USD and the consensus revenue estimate is 206.43M USD.
The next earnings revenue estimate has been revised downward by 3.56% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
MYGN revenue by date.MYGN revenue by date.
753.2M
11.03%		837.6M
11.21%		824.5M
-1.56%		881.27M
6.89%		928.41M
5.35%		975.95M
5.12%		1.055B
8.10%		1.058B
0.28%
EBITDA
YoY % growth
MYGN ebitda by date.MYGN ebitda by date.
-75M
-5.63%		-26.8M
64.27%		-14.1M
47.39%		40.647M
388.28%		48.773M
19.99%		60.966M
25.00%		89.76M
47.23%		108.12M
20.45%
EBIT
YoY % growth
MYGN ebit by date.MYGN ebit by date.
-136.9M
-10.67%		-88M
35.72%		-67.8M
22.95%		14.235M
121.00%		25.529M
79.34%		27.065M
6.02%		72.42M
167.58%		79.56M
9.86%
Operating Margin
MYGN operating margin by date.MYGN operating margin by date.
-18.18%-10.51%-8.22%1.62%2.75%2.77%6.86%7.52%
EPS
YoY % growth
MYGN eps by date.MYGN eps by date.
-0.28
6.67%		0.13
146.43%		0.06
-53.85%		0.06
1.23%		0.19
211.34%		0.30
60.81%		0.61
100.14%		0.67
10.61%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		-0.07
-133.04%		0.01
-75.21%		0.050.06
40.45%		-0.01
85.12%		0.04
224.28%		0.07
50.77%		0.08
46.33%		0.00
100.00%		0.07
64.97%		0.06
-11.11%		0.06
-31.76%
Revenue
Q2Q % growth		206.43M
5.38%		219.25M
2.89%		225.5M
9.63%		230.03M
9.64%		219.12M
6.15%		231.4M
5.54%		238.79M
5.89%		243.22M
5.73%		229.49M
4.73%		243.05M
5.03%		248.71M
4.15%		254.83M
4.77%
EBITDA
Q2Q % growth		524.719K
103.59%		10.708M
-33.07%		12.976M
-27.10%		14.75M
-70.91%		7.686M
1,364.79%		12.389M
15.70%		15.096M
16.34%		16.219M
9.96%		3.213M
-58.20%		17.575M
41.86%		17.269M
14.39%		18.85M
16.22%
EBIT
Q2Q % growth		-6.577M
77.32%		3.847M
130.78%		7.719M
133.13%		9.426M
414.20%		-116.576K
98.23%		7.232M
87.99%		10.789M
39.77%		12.542M
33.06%		-3.682M
-3,058.63%		10.822M
49.64%		10.455M
-3.10%		12.036M
-4.03%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

MYGN Yearly Revenue VS EstimatesMYGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
MYGN Yearly EPS VS EstimatesMYGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
71.77%
EPS Next 5 Year
62.18%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
5.18%
Revenue Next 5 Year
4.76%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
103.71%
EBIT Next 5 Year
71.86%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

MYRIAD GENETICS INC / MYGN Forecast FAQ

What is the average price target for MYRIAD GENETICS INC (MYGN) stock?

18 analysts have analysed MYGN and the average price target is 7.54 USD. This implies a price increase of 72.91% is expected in the next year compared to the current price of 4.36.

When does MYRIAD GENETICS INC (MYGN) report earnings?

MYRIAD GENETICS INC (MYGN) will report earnings on 2026-05-04, after the market close.

What are the consensus estimates for MYRIAD GENETICS INC (MYGN) next earnings?

The consensus EPS estimate for the next earnings of MYRIAD GENETICS INC (MYGN) is -0.07 USD and the consensus revenue estimate is 206.43M USD.

Can you provide the consensus rating for MYRIAD GENETICS INC stock?

The consensus rating for MYRIAD GENETICS INC (MYGN) is 53.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.